Skip to main content
lexblog.com/lib/N7KKK5JCviewrecordjson
{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Litigation vs. Licensing: Manufacturers of the Two Most Recently Approved Biosimilars Take Different Approaches to Reference Drug Patents",
    "url": "https://www.mccarter.com/insights/business-litigators-edge-tips-for-litigating-in-new-jersey-federal-and-state-courts/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-N7KKK5JC",
        "url": "https://www.lexblog.com/lib/N7KKK5JC/"
    },
    "datePublished": "2017-12-05T19:39:08-05:00",
    "dateModified": "2021-11-09T11:33:36-05:00",
    "author": {
        "@type": "Person",
        "name": "Benjamin R. Holt"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Rothwell Figg"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Biosimilars Law Bulletin",
    "about": "Health Care and Life Sciences ยท Intellectual Property",
    "sourceUrl": "http://www.biosimilarsip.com/?p=4207",
    "sourceStability": "may-move"
}